|Day Low/High||223.62 / 230.31|
|52 Wk Low/High||177.05 / 276.69|
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
RMPIA outperformed once gain during April.
Plus a possible setup in Amgen as earnings approach.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
In this day and age, companies must be 'disruptors' or get left in the dust.
The RMPIA rose 10.5% during the first half of the current quarter.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Apple shares are up nearly 4% in after-hours trading.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
So far 2019 is proving to be a year where things have a habit of working out right.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
For the month of November RMPIA climbed 1.2% month over month.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Investors should continue to hold Amgen.